Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study - The Lancet Regional Health – Americas
IJMS | Free Full-Text | How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Biomedicines | Free Full-Text | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram
Triple negative breast cancer therapies nanomedicine - Inside Tx
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden | BMC Cancer | Full Text
Breast cancer-specific survival by body mass index categories for... | Download Scientific Diagram
Luminal B Breast Cancer: Symptoms, Diagnosis, and Treatment
Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy | Scientific Reports
Breast Cancer Subtypes And Prognosis | BCTT
Breast Cancer Types | Breast Cancer Trials
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer | npj Breast Cancer
Breast Cancer Subtypes And Prognosis | BCTT
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes | BMC Women's Health | Full Text
The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score - Yang - 2023 - Cancer Medicine - Wiley Online Library
